SCHEMBL507688

SCHEMBL507688

Clc1cc(CBr)ccc1Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
IDO1 P14902 2/20 0.38
ALDH1A1 P00352 4/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
LMNA P02545 3/20 0.38
GAA P10253 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP3A4 P08684 5/20 0.37
MAPT P10636 2/20 0.36
HPGD P15428 1/20 0.36
PNMT P11086 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
SLC6A2 P23975 5/20 0.35
SLC6A4 P31645 5/20 0.35
SLC6A3 Q01959 5/20 0.35
CYP2D6 P10635 4/20 0.35
KCNH2 Q12809 4/20 0.35
TRPA1 O75762 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2294256 0.82 PNMT (0.42) IDO1ALDH1A1MEN1KMT2ALMNA
SCHEMBL30488129 0.81 CYP4F2 (0.43) CYP4F2CYP4A11IDO1ALDH1A1KMT2A
SCHEMBL507167 0.81 CYP4F2 (0.43) CYP4F2CYP4A11IDO1ALDH1A1KMT2A
SCHEMBL1535743 0.81 IDO1 (0.38) IDO1ALDH1A1MEN1KMT2ALMNA
SCHEMBL29413271 0.80 IDO1 (0.58) CYP4F2CYP4A11IDO1PNMTTAAR1
SCHEMBL10128 0.80 IDO1 (0.58) CYP4F2CYP4A11IDO1PNMTTAAR1
SCHEMBL257061 0.79 ALDH1A1 (0.42) CYP4F2CYP4A11IDO1ALDH1A1MEN1
SCHEMBL2522185 0.79 RECQL (0.42) IDO1ALDH1A1MEN1KMT2ALMNA
SCHEMBL29973253 0.79 RECQL (0.42) IDO1ALDH1A1MEN1KMT2ALMNA
SCHEMBL30003904 0.79 CSNK2A1 (0.50) IDO1CYP3A4PNMTTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479816-B2 20-HETE formation inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-11-25 US disclosed
CN-115151553-B Boric acid derivatives 首药控股(北京)股份有限公司 2025-06-13 CN disclosed
US-20250188070-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2025-06-12 US disclosed
CN-112236428-B Antiproliferative compounds and uses thereof 默克专利股份有限公司 2025-04-01 CN disclosed
US-12195453-B2 Antiproliferation compounds and uses thereof MERCK PATENT GMBH (DE) 2025-01-14 US disclosed
EP-3634404-B1 PYRAZOLE MAGL INHIBITORS H LUNDBECK AS (DK) 2024-11-20 EP disclosed
US-20240239816-A1 BORONO-PHENYLALANINE DERIVATIVE STELLA PHARMA CORPORATION (JP) 2024-07-18 US disclosed
EP-4393919-A1 LSD1 MODULATORS Exscientia Al Limited (GB) 2024-07-03 EP disclosed
EP-4043460-B1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2024-06-05 EP disclosed
EP-4361159-A1 BORONO-PHENYLALANINE DERIVATIVE Stella Pharma Corporation (JP) 2024-05-01 EP disclosed
WO-2005082859-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2005-09-09 WO disclosed
EP-1218401-B1 4-BENZYLAMINOQUINOLINE CONJUGATES WITH BILE ACID AND THEIR HETEROANALOGUES, METHODS FOR PRODUCING THE SAME, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THEIR USE AVENTIS PHARMA GMBH (DE) 2004-06-16 EP disclosed
EP-1218401-A1 4-BENZYLAMINOQUINOLINE CONJUGATES WITH BILE ACID AND THEIR HETEROANALOGUES, METHODS FOR PRODUCING THE SAME, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THEIR USE Aventis Pharma Deutschland GmbH (DE) 2002-07-03 EP disclosed
US-6339077-B1 FOR PROPHYLAXIS OR OF GALLSTONES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-01-15 US disclosed
WO-2001021642-A1 4-BENZYLAMINOQUINOLINE CONJUGATES WITH BILE ACID AND THEIR HETEROANALOGUES, METHODS FOR PRODUCING THE SAME, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THEIR USE AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-03-29 WO disclosed
US-4393062-A ALDOSE REDUCTASE INHIBITOR IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1983-07-12 US disclosed
EP-0002895-B1 ENZYME INHIBITORY PHTHALAZIN-4-YLACETIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND PROCESS FOR THEIR MANUFACTURE IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1981-10-14 EP disclosed
US-4251528-A ALDOSE REDUCTASE INHIBITORS USEFUL IN DIABETES, GALACTOSEMIA IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1981-02-17 US disclosed
US-4185992-A Imidazole derivatives MAY & BAKER LIMITED (GB) 1980-01-29 US disclosed
EP-0002895-A1 Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof, and process for their manufacture IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1979-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239816-A1 BORONO-PHENYLALANINE DERIVATIVE SLC7A1, SLC1A5, LATS2 CYP4F2 201/4885CYP4A11 1151/4885IDO1 1847/4885
US-12195453-B2 Antiproliferation compounds and uses thereof MKI67, MCL1, CCNI CYP4F2 2656/4885CYP4A11 1431/4885IDO1 2742/4885
US-12479816-B2 20-HETE formation inhibitors CYP4A22, ALOX5, ALOX15 CYP4F2 40/4885CYP4A11 10/4885IDO1 638/4885
US-20250188070-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MKI67, MCL1, CCNI CYP4F2 2656/4885CYP4A11 1431/4885IDO1 2742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.